ARQT vs. SMMT

Last updated Apr 2, 2026

Compare and contrast key facts about Arcutis Biotherapeutics, Inc. (ARQT) and Summit Therapeutics Inc. (SMMT).

Performance

ARQT vs. SMMT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Arcutis Biotherapeutics, Inc. (ARQT) and Summit Therapeutics Inc. (SMMT). The values are adjusted to include any dividend payments, if applicable.

ARQT vs. SMMT - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020
ARQT Arcutis Biotherapeutics, Inc.	-17.01%	108.47%	331.27%	-78.18%	-28.64%	-26.27%	29.04%
SMMT Summit Therapeutics Inc.	8.18%	-1.99%	583.72%	-38.59%	57.99%	-42.77%	207.29%

Fundamentals

EPS ARQT : -$0.12 SMMT : -$1.24
Total Revenue (TTM) ARQT : $376.07M SMMT : $0.00
Gross Profit (TTM) ARQT : $339.38M SMMT : -$15.04M
EBITDA (TTM) ARQT : -$1.11M SMMT : -$921.46M

Returns By Period

In the year-to-date period, ARQT achieves a -17.01% return, which is significantly lower than SMMT's 8.18% return.

ARQT

• 1D: 2.29%
• 1M: -2.67%
• YTD: -17.01%
• 6M: 21.96%
• 1Y: 60.88%
• 3Y*: 29.88%
• 5Y*: -4.12%
• 10Y*: —

SMMT

• 1D: -0.21%
• 1M: 16.86%
• YTD: 8.18%
• 6M: -7.66%
• 1Y: 0.64%
• 3Y*: 121.12%
• 5Y*: 25.24%
• 10Y*: 10.52%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

ARQT vs. SMMT — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ARQT

ARQT Risk / Return Rank: 72
ARQT Sharpe Ratio Rank: 74
ARQT Sortino Ratio Rank: 74
ARQT Omega Ratio Rank: 69
ARQT Calmar Ratio Rank: 72
ARQT Martin Ratio Rank: 72

SMMT

SMMT Risk / Return Rank: 43
SMMT Sharpe Ratio Rank: 40
SMMT Sortino Ratio Rank: 46
SMMT Omega Ratio Rank: 49
SMMT Calmar Ratio Rank: 39
SMMT Martin Ratio Rank: 39

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ARQT vs. SMMT - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Arcutis Biotherapeutics, Inc. (ARQT) and Summit Therapeutics Inc. (SMMT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	ARQT	SMMT	Difference
Sharpe ratio Return per unit of total volatility	1.02	0.01	+1.01
Sortino ratio Return per unit of downside risk	1.85	0.69	+1.16
Omega ratio Gain probability vs. loss probability	1.22	1.11	+0.11
Calmar ratio Return relative to maximum drawdown	1.69	-0.03	+1.72
Martin ratio Return relative to average drawdown	3.97	-0.04	+4.01
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

ARQT vs. SMMT - Sharpe Ratio Comparison

The current ARQT Sharpe Ratio is 1.02, which is higher than the SMMT Sharpe Ratio of 0.01. The chart below compares the historical Sharpe Ratios of ARQT and SMMT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	ARQT	SMMT	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.02	0.01	+1.01
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.06	0.14	-0.19
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.07	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.02	0.04	-0.02

Correlation

The correlation between ARQT and SMMT is 0.25, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

ARQT vs. SMMT - Dividend Comparison

Neither ARQT nor SMMT has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

ARQT vs. SMMT - Drawdown Comparison

The maximum ARQT drawdown since its inception was -95.02%, roughly equal to the maximum SMMT drawdown of -95.75%. Use the drawdown chart below to compare losses from any high point for ARQT and SMMT.

Drawdown Indicators

	ARQT	SMMT	Difference
Max Drawdown Largest peak-to-trough decline	-95.02%	-95.75%	+0.73%
Max Drawdown (1Y) Largest decline over 1 year	-31.99%	-62.26%	+30.27%
Max Drawdown (5Y) Largest decline over 5 years	-94.71%	-91.96%	-2.75%
Max Drawdown (10Y) Largest decline over 10 years	—	-95.75%	—
Current Drawdown Current decline from peak	-34.83%	-48.45%	+13.62%
Average Drawdown Average peak-to-trough decline	-50.46%	-57.79%	+7.33%
Ulcer Index Depth and duration of drawdowns from previous peaks	13.63%	44.34%	-30.71%

Volatility

ARQT vs. SMMT - Volatility Comparison

The current volatility for Arcutis Biotherapeutics, Inc. (ARQT) is 15.32%, while Summit Therapeutics Inc. (SMMT) has a volatility of 21.21%. This indicates that ARQT experiences smaller price fluctuations and is considered to be less risky than SMMT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	ARQT	SMMT	Difference
Volatility (1M) Calculated over the trailing 1-month period	15.32%	21.21%	-5.89%
Volatility (6M) Calculated over the trailing 6-month period	43.81%	43.86%	-0.05%
Volatility (1Y) Calculated over the trailing 1-year period	60.16%	93.41%	-33.25%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	71.95%	185.23%	-113.28%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	77.53%	145.07%	-67.54%

Financials